Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2483-2489

  Furumai, Ryohei ^a   Uchida, Kazuyo ^b   Komi, Yusuke ^b   Yoneyama, Misao ^a   Ishigami, Ken ^c   Watanabe, Hidenori ^c   Kojima, Soichi ^b   Yoshida, Minoru ^a,b,d  

^a Chemical Genetics Laboratory   (Japan)

^b RIKEN   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NATURAL PRODUCT; SPLICEOSTATIN A; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CHEMICAL STRUCTURE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; SPLICEOSOME; TUMOR CELL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPIRO COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77958572450     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01686.x     Document Type: Article

References (28)

1. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3(5): 391-400.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
3. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175(3): 409-16.
4. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 2001(112): RE21.
5. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009; 29(6): 789-91.
6. De Bazelaire C, Alsop DC, George D et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008; 14(17): 5548-54.
7. Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008; 35(3): 274-85.
8. William WN Jr, Kies MS, Fossella FV et al. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 2010; 116(10): 2401-8.
9. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in cancer patients receiving antiangiogenesis agents. J Clin Oncol 2009; 27(29): 4865-73.
10. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94(15): 8104-9.
11. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8(11): 880-7.
12. Bates DO, Cui TG, Doughty JM et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62(14): 4123-31.
13. Ray PS, Jia J, Yao P, Majumder M, Hatzoglou M, Fox PL. A stress-responsive RNA switch regulates VEGFA expression. Nature 2009; 457(7231): 915-9.
14. Kramer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu Rev Biochem 1996; 65: 367-409.
15. Nagai K, Muto Y, Pomeranz Krummel DA et al. Structure and assembly of the spliceosomal snRNPs. Novartis Medal Lecture. Biochem Soc Trans 2001; 2: 15-26.
16. Kaida D, Motoyoshi H, Tashiro E et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007; 3(9): 576-83.
17. Lo CW, Kaida D, Nishimura S et al. Inhibition of splicing and nuclear retention of pre-mRNA by spliceostatin A in fission yeast. Biochem Biophys Res Commun 2007; 364(3): 573-7.
18. Kotake Y, Sagane K, Owa T et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007; 3(9): 570-5.
19. Sakai T, Sameshima T, Matsufuji M, Kawamura N, Dobashi K, Mizui Y. Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. I. Taxonomy, fermentation, isolation and screening. J Antibiot (Tokyo) 2004; 57(3): 173-9.
20. Sakai T, Asai N, Okuda A, Kawamura N, Mizui Y. Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. II. Physico-chemical properties and structure elucidation. J Antibiot (Tokyo) 2004; 57(3): 180-7.
21. Komi Y, Sogabe Y, Ishibashi N et al. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab Invest 2010; 90(1): 52-60.
22. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001; 98(1): 87-92.
23. Komi Y, Suzuki Y, Shimamura M et al. Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin. Cancer Sci 2009; 100(2): 269-77.
24. Komi Y, Ohno O, Suzuki Y et al. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin. Jpn J Clin Oncol 2007; 37(11): 867-73.
25. Ribatti D, Nico B, Vacca A, Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 2006; 1(1): 85-91.
26. Hampsey M, Reinberg D. Tails of intrigue: phosphorylation of RNA polymerase II mediates histone methylation. Cell 2003; 113(4): 429-32.
27. Helotera H, Alitalo K. The VEGF family, the inside story. Cell 2007; 130(4): 591-2.
28. Nowak DG, Amin EM, Rennel ES et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 2010; 285(8): 5532-40.